MIF-1: dosing and reconstitution
> Updated:
Calculate the MIF-1 (Pro-Leu-Gly-NH₂) dose
The calculator is already set up for MIF-1 (Pro-Leu-Gly-NH₂) — adjust the dose or diluent volume for your vial.
Human dosing
| Period / condition | Dose | Escalation |
|---|---|---|
| Base cycle (day 1–5) | 10 mg subcutaneously, once daily, 5 consecutive days | Starting dose |
| Repeat cycle | 10 mg/day × 5 days after a 2-day to 1–2-week washout | , |
| Higher doses | 75 mg/day orally in some reports gave a weaker effect than the low dose | Maximum in this schedule (inverted-U curve) |
Practical dosing and effect details
Pilot studies of MIF-1 (Pro-Leu-Gly-NH2) show a pattern pharmacologists call an inverted-U dose-response curve: the effect increases with dose only up to a point, and beyond that point a higher dose weakens the result rather than strengthening it. That is exactly what the table above shows: 75 mg taken orally gave a weaker result in some reports than a much lower dose. A non-monotonic dose response like this is not unusual in peptide pharmacology, though the specific mechanism for MIF-1 itself has not been established. That is why the schedule on this page does not follow a more-is-better logic: the base subcutaneous cycle (10 mg daily for 5 consecutive days) was set for a specific experiment, and the repeat cycle after a 2-day to 2-week washout follows the same approach: a short administration window with a break, not a continuous dose increase. This is reference information for planning a research protocol, not a medical recommendation and not instructions for self-administration.
How to reconstitute
An example reconstitution for convenient dosing. The exact ratios depend on your vial. For research reference only — not medical guidance.
- 1Add the diluentUse bacteriostatic water. Example: 2 ml into a 10 mg vial.MIF-1 (Pro-Leu-Gly-NH₂)10 mg+ 2 mlDiluent
- 2Get the concentrationExample: 10 mg in 2 ml =MIF-1 (Pro-Leu-Gly-NH₂)5 mg/ml(5,000 mcg/ml)
- 3Work out the volume per doseFor example, for a 10 mg dose:10 mg = 2 ml= 200 u. (U-100)
This is only an example calculation. You can use a different diluent volume — plug your own numbers into the calculator. Open calculator →
Research protocols
MIF-1: reference regimens
MIF-1 (Pro-Leu-Gly-NH2) was given by subcutaneous injection in the available studies.
MIF-1 dosing in pilot protocols does not scale up in a straight line: 10 mg subcutaneously daily in short cycles produces a different effect profile than the much higher oral doses that some reports found weaker than the lower dose.
More scientific background in the MIF-1 (Pro-Leu-Gly-NH₂) monograph
Notes and safety
- • MIF-1 (Pro-Leu-Gly-NH₂) is a research peptide. Human safety and efficacy data are limited.
- • The regimens shown are based on publications and research protocols, not clinical recommendations.
- • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
- • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
- • This information is for educational purposes and is not medical advice.
MIF-1 (Pro-Leu-Gly-NH₂)